Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Young researchers shine during the international Afromontane Colloquium
2017-07-18

 Description: Afromontane Colloquium  Tags: Afromontane Colloquium  

From the left, are: Drs Reetu Sogani (India),
Greg Greenwood (US-Switzerland), Teboho Manchu,
Acting Campus Principal, Drs Jianchu Xu (China),
Henri Rueff (Switzerland), Glen Taylor, Senior Director:
Research Development; and Dr Elsa Crause,
Campus Vice-Principal: Academic and Research.
Photo: Thabo Kessah

The University of the Free State’s Afromontane Research Unit (ARU), which is situated on the Qwaqwa Campus, has the potential to produce some of the world’s best and dynamic young researchers. This is the view shared by Drs Henri Rueff and Reetu Sogani, who were the keynote speakers during the ARU Colloquium hosted at Golden Gate in the Eastern Free State.

Dr Rueff, a geographer and environmental economist from the Universities of Basel and Bern in Switzerland, was referring to no less than ten Qwaqwa Campus postgraduate students who made oral and poster presentations during the inaugural international colloquium.

Colloquium an opportunity to interact
“You have some of the world’s most motivated and highly skilled students who have the courage to stand in front of extremely critical scientists from all over the globe – and that must be commended,” he said.

Dr Reetu Sogani from India said that her first trip to South Africa did not disappoint. “This colloquium was a very good learning experience for me as I had the opportunity to interact with brilliant and young scientists from this part of the world,” she added.

In closing the colloquium, the Senior Director: Research Development, Dr Glen Taylor, committed the UFS to the success of the unit.

“The ARU will strengthen the research output of the campus. But most important of all, it is setting the research agenda for the Qwaqwa Campus, and for the institution at large, to address the challenges that the surrounding mountain communities are faced with,” he said.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept